HGH Fragment 176-191: Lipolytic Peptide Research Guide
HGH Fragment 176-191 is a modified peptide corresponding to amino acids 176–191 at the C-terminus of the human growth-hormone molecule. It is studied for its selective effect on fat metabolism — stimulating lipolysis while inhibiting lipogenesis — largely independent of the broader growth-promoting effects of full-length GH.
What is HGH Fragment 176-191?
The fragment isolates the lipolytic region of the GH molecule. In research models it is investigated as a tool for studying fat metabolism without the IGF-1-mediated and glycemic effects associated with full GH, making it attractive for body-composition research.
Mechanism of action
- Lipolysis: stimulates breakdown of triglycerides into glycerol and free fatty acids.
- Inhibition of lipogenesis: limits formation of new fatty acids in research models.
- Metabolic-rate research: studied for effects on overall energy expenditure.
Research findings
Preclinical work (primarily animal models, with limited human study) points to consistent reductions in adipose tissue and favorable metabolic markers. As with most research peptides, long-term data remain limited and findings derive from controlled study settings.
Handling for Canadian research labs
- Not authorized by Health Canada for human use — research-chemical handling only.
- Store lyophilized at −20°C; reconstitute with sterile bacteriostatic water using aseptic technique.
- Source from reputable suppliers providing third-party purity testing and a COA.
Explore related metabolic and GH-axis research compounds we carry: Tesamorelin (visceral-fat research), Ipamorelin, and the GLP-1 family Semaglutide / Tirzepatide — all third-party tested to over 99% purity with a COA. Pair with bacteriostatic water.
This guide is part of our Peptides Canada research hub — explore the full library of compound guides.
Disclaimer: Educational and research content only. HGH Fragment 176-191 is discussed strictly as a research chemical, not for human consumption or therapeutic use. All work must comply with Canadian regulations and institutional ethics approvals.